Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis-Reference-Cited by-同舟云学术

Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis

Published:2022-12 Issue:12 Volume:7 Page:2647-2656
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Rossi Giovanni Maria,Maggiore Umberto,Peyronel Francesco,Fenaroli Paride,Delsante Marco,Benigno Giuseppe Daniele,Gianfreda Davide,Urban Maria Letizia,Manna Zerai,Arend Lois Johanna,Bagnasco Serena,Vaglio Augusto,Fiaccadori Enrico,Rosenberg Avi Z.,Hasni Sarfaraz,Manenti Lucio

Publisher

Elsevier BV

Subject

Nephrology

Reference39 articles.

1. The frequency and outcome of lupus nephritis: results from an international inception cohort study;Hanly;Rheumatol (Oxf Engl),2016

2. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period;Adler;Rheumatol (Oxf Engl),2006

3. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients;Cervera;Med (Baltim),2003

4. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis;Moroni;Ann Rheum Dis,2018

5. ESKD, transplantation, and dialysis in lupus nephritis;Sabucedo;Semin Nephrol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Immunological Factors Associated with the Progression of Lupus Nephritis in a Population from the Colombian Caribbean;Biomedicines;2024-09-09

2. Research on the correlation between rash and complement C3, C4 levels and the occurrence and development of lupus nephritis;2024-06-25

3. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models;JCI Insight;2024-06-18

4. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab;Rheumatology;2024-01-12

5. Pre-Treatment Serum Complement 3 Levels And Rituximab Response In Idiopathic Membranous Nephropathy;Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi;2023-11-20